Submitted:
26 May 2025
Posted:
26 May 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Case Description
2.1. Case 1

2.2. Case 2

3. Discussion
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Acknowledgments
References
- Giusti M, Maio A. Acute thyroid swelling with severe hypothyroid myxoedema after COVID-19 vaccination. Clinical Case Reports. (2021) 9(12). [CrossRef]
- Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sánchez Valadez TI, Jara LJ. Two Cases of Graves’ Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants. Thyroid. (2021) 31(9):1436–9. [CrossRef]
- Franquemont S, Galvez J. Subacute Thyroiditis After mRNA Vaccine for Covid-19. Journal of the Endocrine Society. (2021) 5(Supplement_1):A956–7. [CrossRef]
- Bahl S, Babu PM, Capatana F, Khan I, Adlan M, Premawardhana LDKE. Sub-Acute Thyroiditis Presenting as Pyrexia of Uknown Origin. Journal of the Endocrine Society. (2021) 5(Supplement_1):A956–6. [CrossRef]
- Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. Longo DL, editor. New England Journal of Medicine. (2021) 384(7):643–9. [CrossRef]
- Bragazzi NL, Hejly A, Watad A, Adawi M, Amital H, Shoenfeld Y. ASIA syndrome and endocrine autoimmune disorders. Best Practice & Research Clinical Endocrinology & Metabolism. (2020) 34(1):101412. [CrossRef]
- Saranac L, Zivanovic S, Bjelakovic B, Stamenkovic H, Novak M, Kamenov B. Why Is the Thyroid So Prone to Autoimmune Disease. Hormone Research in Paediatrics. (2011) 75(3):157–65. [CrossRef]
- Casto C, Pepe G, Li Pomi A, Corica D, Aversa T, Wasniewska M. Hashimoto’s Thyroiditis and Graves’ Disease in Genetic Syndromes in Pediatric Age. Genes. (2021) 12(2):222. [CrossRef]
- Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States. Clinical Immunology and Immunopathology. (1997) 84(3):223–43. [CrossRef]
- Cappa M, Bizzarri C, Crea F. Autoimmune Thyroid Diseases in Children. Journal of Thyroid Research. (2011) 2011:1–13. [CrossRef]
- Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, et al. Structural Variations in Human ACE2 may Influence its Binding with SARS-CoV-2 Spike Protein. Journal of Medical Virology. (2020) 92(9). [CrossRef]
- Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nature Medicine. (2021) 27(4):1–15. [CrossRef]
- Boaventura P, Macedo S, Ribeiro F, Jaconiano S, Soares P. Post-COVID-19 Condition: Where Are We Now? Life. (2022) 12(4):517. [CrossRef]
- Murugan AK, Alzahrani AS. SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases. Journal of Inflammation Research. (2021) Volume 14:6191–221. [CrossRef]
- Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, et al. Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role? Endocrine Practice. (2021) 27(9):894–902. [CrossRef]
- Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: Clinical and diagnostic criteria. Autoimmunity Reviews. (2014) 13(4-5):391–7. [CrossRef]
- Groenewegen KL, Mooij CF, van Trotsenburg ASP. Persisting symptoms in patients with Hashimoto’s disease despite normal thyroid hormone levels: Does thyroid autoimmunity play a role? A systematic review. Journal of Translational Autoimmunity. (2021) 4:100101. [CrossRef]
- Nikolic DM. Covid-19: A Hypothetical View on Infection. Virology & Immunology Journal. (2020) 4(2):1–3. [CrossRef]
| Patient No 1 | Patient No 2 | |||||
| Type and date of vaccination | 1. AstraZeneca (27.02.2021.) 2. AstraZeneka (21.05.2021.) 3. Pfizer BioNTech (19.11.2021.) |
1.Sinopharm (24.01.2021.) 2. Sinopharm (14.02.2021.) 3. Sinopharm (19.11.2021.) |
||||
| Date of analysis | 28.09.2021. | 4.01.2022. | 21.09.2021. | 10.12.2021. | ||
| Parameters | Value | Value | Reference value | Value | Value | Reference value |
| T3 | 1.21 | 1.09 | 1.10-3.10 | 4.56 | 3.1-6.8 | |
| T4 | 57.9 | 69.88 | 58.0-161.0 | 17.08 | 12-22 | |
| TSH | 16.700 | 25.49 | 0.400-4.00 | 0.400-4.00 | ||
| Anti TPO | 309.5 | 1326.00 | ≤34 | 187.00 | 180.4 | ≤34 |
| Anti Tg | 79.61 | ≤115 | 33.82 | ≤115 | ||
| BMI | 19.15 (normal body weight) | 23.7 (normal body weight) | ||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).